Intellia Therapeutics, Inc. (NTLA) Reaches $21.91 After 3.00% Down Move; Mutual Of America Capital Management Has Decreased By $548,256 Its Boston Scientific (BSX) Stake

April 11, 2018 - By Ellis Scott

Boston Scientific Corporation (NYSE:BSX) Logo

Mutual Of America Capital Management Llc decreased Boston Scientific (BSX) stake by 9.52% reported in 2017Q4 SEC filing. Mutual Of America Capital Management Llc sold 22,844 shares as Boston Scientific (BSX)’s stock rose 7.69%. The Mutual Of America Capital Management Llc holds 217,122 shares with $5.38 million value, down from 239,966 last quarter. Boston Scientific now has $38.46B valuation. The stock decreased 0.07% or $0.02 during the last trading session, reaching $27.88. About 3.14M shares traded. Boston Scientific Corporation (NYSE:BSX) has risen 9.97% since April 11, 2017 and is uptrending. It has underperformed by 1.58% the S&P500.

The stock of Intellia Therapeutics, Inc. (NASDAQ:NTLA) is a huge mover today! The stock decreased 2.10% or $0.47 during the last trading session, reaching $21.91. About 838,035 shares traded. Intellia Therapeutics, Inc. (NASDAQ:NTLA) has risen 65.40% since April 11, 2017 and is uptrending. It has outperformed by 53.85% the S&P500.The move comes after 5 months negative chart setup for the $928.71 million company. It was reported on Apr, 11 by Barchart.com. We have $21.25 PT which if reached, will make NASDAQ:NTLA worth $27.86M less.

Intellia Therapeutics Inc., a gene editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company has market cap of $928.71 million. The firm develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism programs. It currently has negative earnings. The Company’s ex vivo pipeline includes proprietary and partnered programs focuses on chimeric antigen receptor T cells and hematopoietic stem cells.

Among 4 analysts covering Intellia Therapeutics (NASDAQ:NTLA), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Intellia Therapeutics has $39 highest and $33 lowest target. $36’s average target is 64.31% above currents $21.91 stock price. Intellia Therapeutics had 5 analyst reports since May 31, 2016 according to SRatingsIntel. The company was initiated on Tuesday, May 31 by Credit Suisse. The stock has “Outperform” rating by Wedbush on Tuesday, May 31. Jefferies initiated Intellia Therapeutics, Inc. (NASDAQ:NTLA) rating on Tuesday, May 31. Jefferies has “Hold” rating and $33 target. On Friday, August 5 the stock rating was upgraded by Leerink Swann to “Outperform”. The stock has “Buy” rating by Jefferies on Friday, August 5.

Investors sentiment increased to 1.34 in 2017 Q4. Its up 0.30, from 1.04 in 2017Q3. It improved, as 36 investors sold BSX shares while 158 reduced holdings. 86 funds opened positions while 174 raised stakes. 1.18 billion shares or 2.38% less from 1.21 billion shares in 2017Q3 were reported. Welch Forbes Ltd Liability Corp has 402,170 shares. Lpl Ltd Limited Liability Company invested 0.01% in Boston Scientific Corporation (NYSE:BSX). Gradient Ltd Company, a Minnesota-based fund reported 100 shares. Virtus Inv Advisers owns 69,912 shares for 0.07% of their portfolio. Automobile Association stated it has 0.09% of its portfolio in Boston Scientific Corporation (NYSE:BSX). Carroll Fincl Incorporated accumulated 2,727 shares. Verity Asset Management Inc holds 8,027 shares or 0.17% of its portfolio. Rmb Cap Limited has invested 0.01% of its portfolio in Boston Scientific Corporation (NYSE:BSX). Enterprise Financial Serv, a Missouri-based fund reported 9,126 shares. Rhenman And Prtnrs Asset Ab, a Sweden-based fund reported 347,968 shares. Landscape Capital Management Llc stated it has 0.1% in Boston Scientific Corporation (NYSE:BSX). Reilly Financial Limited Liability Corp owns 0% invested in Boston Scientific Corporation (NYSE:BSX) for 411 shares. Moreover, Teacher Retirement Of Texas has 0.06% invested in Boston Scientific Corporation (NYSE:BSX) for 376,275 shares. Silvercrest Asset Management Grp Lc accumulated 0% or 9,843 shares. Jane Street Group Llc invested 0% in Boston Scientific Corporation (NYSE:BSX).

Analysts await Boston Scientific Corporation (NYSE:BSX) to report earnings on April, 26. They expect $0.31 EPS, up 6.90% or $0.02 from last year’s $0.29 per share. BSX’s profit will be $427.64M for 22.48 P/E if the $0.31 EPS becomes a reality. After $0.34 actual EPS reported by Boston Scientific Corporation for the previous quarter, Wall Street now forecasts -8.82% negative EPS growth.

Mutual Of America Capital Management Llc increased Schwab (Charles) (NYSE:SCHW) stake by 7,846 shares to 151,440 valued at $7.78M in 2017Q4. It also upped Bristol (NYSE:BMY) stake by 11,376 shares and now owns 274,214 shares. Kimberly Clark Corp. (NYSE:KMB) was raised too.

Since October 30, 2017, it had 0 buys, and 15 sales for $7.82 million activity. Pierce David A sold $243,074 worth of Boston Scientific Corporation (NYSE:BSX) on Thursday, January 11. Phalen Michael P. had sold 15,835 shares worth $399,865. Ballinger Kevin J. also sold $1.21 million worth of Boston Scientific Corporation (NYSE:BSX) shares. Fitzgerald Joseph Michael sold $2.26 million worth of Boston Scientific Corporation (NYSE:BSX) on Wednesday, February 7. Another trade for 14,150 shares valued at $381,949 was made by Sorenson John Bradley on Thursday, March 1. On Monday, March 19 Brennan Daniel J. sold $1.68 million worth of Boston Scientific Corporation (NYSE:BSX) or 60,209 shares.

Among 32 analysts covering Boston Scientific Corporation (NYSE:BSX), 26 have Buy rating, 0 Sell and 6 Hold. Therefore 81% are positive. Boston Scientific Corporation had 92 analyst reports since July 27, 2015 according to SRatingsIntel. The company was maintained on Friday, July 29 by JP Morgan. The rating was maintained by Needham on Thursday, July 27 with “Buy”. Piper Jaffray initiated the stock with “Buy” rating in Friday, February 23 report. BMO Capital Markets maintained the stock with “Buy” rating in Tuesday, December 12 report. On Monday, October 2 the stock rating was maintained by RBC Capital Markets with “Buy”. The firm has “Buy” rating given on Thursday, November 12 by Citigroup. Needham maintained the stock with “Buy” rating in Friday, April 28 report. The firm has “Strong Buy” rating by Raymond James given on Monday, October 5. The rating was upgraded by Goldman Sachs to “Neutral” on Thursday, August 27. The firm has “Buy” rating by Argus Research given on Thursday, September 1.

Boston Scientific Corporation (NYSE:BSX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 Ellis Scott

Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: